Neurobiology of Aging
Volume 30, Issue 8 , Pages 1217-1226 , August 2009

PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET

  • Sriram Venneti

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Brian J. Lopresti

      Affiliations

    • Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Guoji Wang

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Ronald L. Hamilton

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Chester A. Mathis

      Affiliations

    • Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • William E. Klunk

      Affiliations

    • Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Udayan M. Apte

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Clayton A. Wiley

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • Corresponding Author InformationCorresponding author at: Presbyterian University Hospital, Neuropathology Division, 200 Lothrop Street A515, Pittsburgh, PA 15213, USA. Tel.: +1 412 647 0765; fax: +1 412 647 5602.

Received 14 July 2007 ,Revised 26 October 2007 ,Accepted 4 November 2007.

References 

  1. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819–2826
  2. Bamberger ME, Landreth GE. Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease. Microsc. Res. Technol. 2001;54:59–70
  3. Banati RB, Myers R, Kreutzberg GW. PK (‘peripheral benzodiazepine’)-binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J. Neurocytol. 1997;26:77–82
  4. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000;123(Pt 11):2321–2337
  5. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000;6:916–919
  6. Benveniste EN, Nguyen VT, O’Keefe GM. Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem. Int. 2001;39:381–391
  7. Bianca VD, Dusi S, Bianchini E, Dal Pra I, Rossi F. Beta-amyloid activates the O2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J. Biol. Chem. 1999;274:15493–15499
  8. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939–945
  9. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461–467
  10. Chen MK, Baidoo K, Verina T, Guilarte TR. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain. 2004;127:1379–1392
  11. Dickson DW. Microglia in Alzheimer's disease and transgenic models. How close the fit?. Am. J. Pathol. 1999;154:1627–1631
  12. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11–20
  13. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 1999;22:219–240
  14. Graeber MB, Lowe J, Radotra B. A free community approach to classifying disease. PLoS Med. 2004;1:e16
  15. Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. J. Nucl. Med. 1995;36:2207–2210
  16. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005;25:8843–8853
  17. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005;25:10598–10606
  18. Kuhlmann AC, Guilarte TR. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J. Neurochem. 2000;74:1694–1704
  19. Malm TM, Koistinaho M, Parepalo M, Vatanen T, Ooka A, Karlsson S, et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 2005;18:134–142
  20. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129–131
  21. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285–1291
  22. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J. Neuropathol. Exp. Neurol. 2005;64:743–753
  23. Myers R, Manjil LG, Cullen BM, Price GW, Frackowiak RS, Cremer JE. Macrophage and astrocyte populations in relation to [3H]PK 11195 binding in rat cerebral cortex following a local ischaemic lesion. J. Cereb. Blood Flow. Metab. 1991;11:314–322
  24. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003;9:448–452
  25. Pedersen MD, Minuzzi L, Wirenfeldt M, Meldgaard M, Slidsborg C, Cumming P, et al. Up-regulation of PK11195 binding in areas of axonal degeneration coincides with early microglial activation in mouse brain. Eur. J. Neurosci. 2006;24:991–1000
  26. Raghavendra Rao VL, Dogan A, Bowen KK, Dempsey RJ. Traumatic brain injury leads to increased expression of peripheral-type benzodiazepine receptors, neuronal death, and activation of astrocytes and microglia in rat thalamus. Exp. Neurol. 2000;161:102–114
  27. Schenk DB, Yednock T. The role of microglia in Alzheimer's disease: friend or foe?. Neurobiol. Aging. 2002;23:677–679(discussion 683–674)
  28. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–177
  29. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489–502
  30. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 1997;17:2653–2657
  31. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 1999;154:1673–1684
  32. Stephenson DT, Schober DA, Smalstig EB, Mincy RE, Gehlert DR, Clemens JA. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J. Neurosci. 1995;15:5263–5274
  33. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626–632
  34. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, et al. Microglial activation resulting from CD40–CD40L interaction after beta-amyloid stimulation. Science. 1999;286:2352–2355
  35. in t’Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 2001;345:1515–1521
  36. Venneti S, Lopresti BJ, Wang G, Bissel SJ, Mathis CA, Meltzer CC, et al. PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. J. Clin. Invest. 2004;113:981–989
  37. Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neurosci. Res. 1997;50:345–353
  38. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004;24:6144–6151

PII: S0197-4580(07)00422-8

doi: 10.1016/j.neurobiolaging.2007.11.005

Neurobiology of Aging
Volume 30, Issue 8 , Pages 1217-1226 , August 2009

Article Tools

* Image Usage & Resolution